|
Factors
| |
Median survival
|
P-value
|
|---|
| | |
(months)
| |
|---|
|
Age (yrs)
|
≤60
|
9.8 ± 4.9
|
0.585
|
| |
>60
|
13.6 ± 2.1
| |
|
Gender
|
Male
|
12.9 ± 1.9
|
0.293
|
| |
Female
|
11.6 ± 1.0
| |
|
ECOG
|
1
|
15.9 ± 4.0
|
0.070
|
| |
2
|
9.8 ± 3.1
| |
|
Etiology
|
Viral
|
11.3 ± 1.4
|
0.344
|
| |
Non-viral
|
13.6 ± 2.2
| |
|
Child-Pugh
|
A
|
13.0 ± 1.5
|
0.309
|
|
Classification
|
B
|
6.4 ± 0.8
| |
|
JIS score
|
2
|
13.0 ± 1.4
|
0.235
|
| |
3
|
5.8 ± 0.3
| |
|
Pretreatment
|
≤ 20
|
15.9 ± 1.6
|
0.161
|
|
AFP (ng/ml)
|
> 20
|
10.9 ± 1.0
| |
|
Type of HCC
|
Nodular
|
11.3 ± 0.7
|
0.853
|
| |
Diffuse infiltrative
|
13.6 ± 4.4
| |
|
Multiplicity
|
Solitary
|
11.3 ± 1.3
|
0.534
|
| |
Multiple
|
13.9 ± 2.1
| |
|
Location of thrombi
|
PV branch
|
16.6 ± 5.9
|
0.036
|
| |
Main portal trunk
|
9.8 ± 4.2
| |
|
BED (Gy10)
|
< 75
|
13.0 ± 1.4
|
0.901
|
| |
≥ 75
|
9.8 ± 4.7
| |
|
PVTT response
|
CR + PR
|
13.9 ± 1.1
|
0.142
|
| |
SD + PD
|
6.9 ± 5.1
| |
- Abbreviations: ECOG, Eastern Cooperative Oncology Group; JIS, Japan integrated staging; AFP, α-fetoprotein; HCC, Hepatocellular carcinoma; PV, Portal vein; BED, biologically effective dose; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
- P-values are obtained by log-rank test.
